BioCentury
ARTICLE | Company News

Amgen, Xencor partner on bispecific antibodies

September 17, 2015 1:38 AM UTC

Amgen Inc. (NASDAQ:AMGN) and Xencor Inc. (NASDAQ:XNCR) partnered to develop six preclinical programs in cancer and inflammation using Xencor's XmAb bispecific antibody platform.

Xencor President and CEO Bassil Dahiyat told BioCentury that Xencor will use its bispecific Fc domain technology to create five bispecific antibodies based on starting antibodies and targets preselected by Amgen. Amgen will be responsible for development and commercialization, and have exclusive rights to develop bispecific antibodies against the specified target pairs. Amgen will also take over a sixth preclinical Xencor bispecific T cell engager program against CD38 and CD3 to treat multiple myeloma (MM), including XmAb13551. ...